395 related articles for article (PubMed ID: 10326746)
1. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
Lund B; Hansen OP; Hansen HH; Hansen M
Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of high-dose cisplatin plus ifosfamide as first-line followed by carboplatin as second-line treatment in epithelial ovarian carcinoma.
Strauss G; Lund B; Hansen M; Hansen HH
Gynecol Oncol; 1997 Jul; 66(1):66-70. PubMed ID: 9234923
[TBL] [Abstract][Full Text] [Related]
6. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
8. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
Fanning J; Hilgers RD
Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
10. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
Bolis G; Scarfone G; Giardina G; Villa A; Mangili G; Melpignano M; Presti M; Tateo S; Franchi M; Parazzini F;
Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy of advanced ovarian cancer.
Martoni A; Cacciari N; Angelelli B; Zamagni C; Pannuti F
Front Biosci; 1997 Mar; 2():g20-6. PubMed ID: 9159262
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Zanetta G; Fei F; Mangioni C
Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
[TBL] [Abstract][Full Text] [Related]
14. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study.
Miglietta L; Amoroso D; Bruzzone M; Granetto C; Catsafados E; Mammoliti S; Guarneri D; Pedulla F; Foglia G; Ragni N; Martini MC; Brema F; Addamo G; Moraglio L; Pastorino G; Boccardo F
Oncology; 1997; 54(2):102-7. PubMed ID: 9075779
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
17. Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease.
Lund B; Hansen M; Hansen OP; Hansen HH
J Clin Oncol; 1990 Jul; 8(7):1226-30. PubMed ID: 2113570
[TBL] [Abstract][Full Text] [Related]
18. Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen.
Bolis G; Scarfone G; Luchini L; Ferraris C; Zanaboni F; Presti M; Giardina G; Villa A; Parazzini F
Eur J Cancer; 1994; 30A(12):1764-8. PubMed ID: 7880602
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
Grem J; O'Dwyer P; Elson P; Simon N; Trump D; Frontiera M; Falkson G; Vogl S
J Clin Oncol; 1991 Oct; 9(10):1793-800. PubMed ID: 1919629
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
Swenerton K; Jeffrey J; Stuart G; Roy M; Krepart G; Carmichael J; Drouin P; Stanimir R; O'Connell G; MacLean G
J Clin Oncol; 1992 May; 10(5):718-26. PubMed ID: 1569444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
